FDA Releases Final Guidance for Generic Transdermal and Topical Drug Adhesion Assessment

The FDA has issued final guidance for industry on evaluating the adhesion properties of generic transdermal and topical drug products. This update provides recommendations for Abbreviated New Drug Applications (ANDAs), aiming to ensure the quality and performance of these drug delivery systems. The guidance is important for pharmaceutical manufacturers developing generic versions of patches and creams.